Alzheimer’s Accountability and Investment Act
Summary
The Alzheimer’s Accountability and Investment Act (S.134, Public Law 118-93) was signed into law on October 1, 2024. It mandates that the NIH annually submit a budget estimate for Alzheimer's initiatives directly to the President for transmittal to Congress, but does not allocate any funding or impose requirements on private companies. This procedural law has no direct market impact.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The law is procedural and does not allocate funds or mandate spending.
- 2.No direct impact on Alzheimer's drug developers or diagnostics companies.
- 3.Future appropriations could be influenced by NIH budget estimates, but this is not guaranteed.
Market Implications
No market implications. The law does not create contracts, grants, or tax incentives. Alzheimer's-related stocks (BIIB, LLY, RHHBY) are not affected.
Full Analysis
The bill, introduced by Senator Collins (R-ME) and passed unanimously, became law in October 2024. It amends the National Alzheimer's Project Act to require the NIH Director to prepare and submit a 'professional judgment budget' for Alzheimer's research initiatives directly to the President, bypassing HHS review authority (though HHS and the Advisory Council may comment). The law does not authorize or appropriate any specific dollar amount; it only requires an annual budget estimate. Since no funds are directed to any company or research program, the market implications are nil. The law is procedural, altering the budget submission process within the executive branch. No new programs, mandates, or incentives for drug developers or diagnostic companies were created. The Alzheimer's research ecosystem may benefit indirectly if future appropriations are shaped by these estimates, but that is uncertain and not part of this law. Investors should not expect any near-term revenue changes for Alzheimer's-related companies such as Biogen (BIIB), Eli Lilly (LLY), or others from this action.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
NAPA Reauthorization Act
To amend title XVIII of the Social Security Act to allow individuals with Alzheimer's disease to buy in to the Medicare program.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Accelerating Access To Veterans' Benefits And Employment Opportunities
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →